Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos and Arthrogen Pen Rheumatoid Arthritis Gene Therapy Target-Discovery Deal

NEW YORK, March 30 (GenomeWeb News) - Galapagos has signed a three-year agreement with Arthrogen to discover gene therapy targets related to rheumatoid arthritis, Galapagos said today.

 

Under the terms of the agreement, Galapagos' service division, BioFocus, will discover, characterize, and validate candidate protein targets in return for an upfront payment, R&D funding, and milestone payments provided by Arthrogen, the companies said.

 

Total revenues associated with a qualifying target may exceed €7.5 million ($9 million), the companies added.

 

Arthrogen is a joint venture of the Dubai Bone & Joint Center and the Academic Medical Center in Amsterdam.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.